The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
2,301
100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
Proportion of subjects achieving PGA "clear" (0) or "minimal" (1) scores by visit.
Time frame: Visit (12 weeks)
Proportion of subjects achieving a > PASI 50 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit.
Time frame: Visit (12 weeks)
Proportion of subjects achieving a > PASI 75 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit.
Time frame: Visit (12 weeks)
AEs, serious adverse events (SAEs), laboratory data, ADA and vital signs will be assessed throughout the study
Time frame: Visit (12 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site Reference ID/Investigator# 7496
Birmingham, Alabama, United States
Site Reference ID/Investigator# 8438
Birmingham, Alabama, United States
Site Reference ID/Investigator# 7522
Huntsville, Alabama, United States
Site Reference ID/Investigator# 7774
Scottsdale, Arizona, United States
Site Reference ID/Investigator# 7435
Tucson, Arizona, United States
Site Reference ID/Investigator# 7933
Little Rock, Arkansas, United States
Site Reference ID/Investigator# 7234
Bakersfield, California, United States
Site Reference ID/Investigator# 8249
Fresno, California, United States
Site Reference ID/Investigator# 7332
Irvine, California, United States
Site Reference ID/Investigator# 7239
Los Angeles, California, United States
...and 142 more locations